Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1987 1
1988 2
1989 4
1990 10
1991 4
1992 8
1993 8
1994 11
1995 6
1996 9
1997 12
1998 9
1999 5
2000 9
2001 12
2002 10
2003 14
2004 14
2005 10
2006 14
2007 6
2008 11
2009 28
2010 18
2011 20
2012 34
2013 29
2014 37
2015 49
2016 47
2017 59
2018 60
2019 71
2020 69
2021 83
2022 49
2023 42

Text availability

Article attribute

Article type

Publication date

Search Results

800 results

Results by year

Filters applied: . Clear all
Page 1
Pediatric acute lymphoblastic leukemia.
Inaba H, Mullighan CG. Inaba H, et al. Haematologica. 2020 Nov 1;105(11):2524-2539. doi: 10.3324/haematol.2020.247031. Haematologica. 2020. PMID: 33054110 Free PMC article. Review.
The last decade has witnessed great advances in our understanding of the genetic and biological basis of childhood acute lymphoblastic leukemia (ALL), the development of experimental models to probe mechanisms and evaluate new therapies, and the develo …
The last decade has witnessed great advances in our understanding of the genetic and biological basis of childhood acute ly
International Consensus Classification of acute lymphoblastic leukemia/lymphoma.
Duffield AS, Mullighan CG, Borowitz MJ. Duffield AS, et al. Virchows Arch. 2023 Jan;482(1):11-26. doi: 10.1007/s00428-022-03448-8. Epub 2022 Nov 24. Virchows Arch. 2023. PMID: 36422706 Free PMC article. Review.
The updated International Consensus Classification (ICC) of B-acute lymphoblastic leukemia (B-ALL) and T-acute lymphoblastic leukemia (T-ALL) includes both revisions to subtypes previously outlined in the 2016 WHO classifica …
The updated International Consensus Classification (ICC) of B-acute lymphoblastic leukemia (B-ALL) and T-acut
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion.
Amini L, Silbert SK, Maude SL, Nastoupil LJ, Ramos CA, Brentjens RJ, Sauter CS, Shah NN, Abou-El-Enein M. Amini L, et al. Nat Rev Clin Oncol. 2022 May;19(5):342-355. doi: 10.1038/s41571-022-00607-3. Epub 2022 Mar 22. Nat Rev Clin Oncol. 2022. PMID: 35318469 Review.
However, in order to derive the desired level of effectiveness, patients need to successfully receive the CAR T cell infusion in a timely fashion. This process entails apheresis of the patient's T cells, followed by CAR T cell manufacture. ...In …
However, in order to derive the desired level of effectiveness, patients need to successfully receive the CAR T cell infusion …
Acute lymphoblastic leukemia: a comprehensive review and 2017 update.
Terwilliger T, Abdul-Hay M. Terwilliger T, et al. Blood Cancer J. 2017 Jun 30;7(6):e577. doi: 10.1038/bcj.2017.53. Blood Cancer J. 2017. PMID: 28665419 Free PMC article. Review.
Acute lymphoblastic leukemia (ALL) is the second most common acute leukemia in adults, with an incidence of over 6500 cases per year in the United States alone. The hallmark of ALL is chromosomal abnormalities and genetic alterations involved in
Acute lymphoblastic leukemia (ALL) is the second most common acute leukemia in adults, with an incidence
Mechanisms of resistance to CAR T cell therapy.
Shah NN, Fry TJ. Shah NN, et al. Nat Rev Clin Oncol. 2019 Jun;16(6):372-385. doi: 10.1038/s41571-019-0184-6. Nat Rev Clin Oncol. 2019. PMID: 30837712 Free PMC article. Review.
The successes with chimeric antigen receptor (CAR) T cell therapy in early clinical trials involving patients with pre-B cell acute lymphoblastic leukaemia (ALL) or B cell lymphomas have revolutionized anticancer therapy, providing a pote …
The successes with chimeric antigen receptor (CAR) T cell therapy in early clinical trials involving patients with pre-B ce
The New Therapeutic Strategies in Pediatric T-Cell Acute Lymphoblastic Leukemia.
Lato MW, Przysucha A, Grosman S, Zawitkowska J, Lejman M. Lato MW, et al. Int J Mol Sci. 2021 Apr 26;22(9):4502. doi: 10.3390/ijms22094502. Int J Mol Sci. 2021. PMID: 33925883 Free PMC article. Review.
Childhood acute lymphoblastic leukemia is a genetically heterogeneous cancer that accounts for 10-15% of T-cell acute lymphoblastic leukemia (T-ALL) cases. ...These include therapies that inhibit Notch1 activat
Childhood acute lymphoblastic leukemia is a genetically heterogeneous cancer that accounts for 10-15% of T
T cell-engaging therapies - BiTEs and beyond.
Goebeler ME, Bargou RC. Goebeler ME, et al. Nat Rev Clin Oncol. 2020 Jul;17(7):418-434. doi: 10.1038/s41571-020-0347-5. Epub 2020 Apr 2. Nat Rev Clin Oncol. 2020. PMID: 32242094 Review.
Immuno-oncology approaches have entered clinical practice, with tremendous progress particularly in the field of T cell-engaging therapies over the past decade. Herein, we provide an overview of the current status of bispecific T cell engager (BiTE) th …
Immuno-oncology approaches have entered clinical practice, with tremendous progress particularly in the field of T cell-engagi …
Immunotherapy in pediatric acute lymphoblastic leukemia.
Inaba H, Pui CH. Inaba H, et al. Cancer Metastasis Rev. 2019 Dec;38(4):595-610. doi: 10.1007/s10555-019-09834-0. Cancer Metastasis Rev. 2019. PMID: 31811553 Free PMC article. Review.
The 5-year survival rate for children and adolescents with acute lymphoblastic leukemia (ALL) has improved to more than 90% in high-income countries. ...For immunotherapy, the approval of antibody-based therapy (with blinatumomab in 2014 and inotuzumab ozogam …
The 5-year survival rate for children and adolescents with acute lymphoblastic leukemia (ALL) has improved to more than …
Genetic Basis of Acute Lymphoblastic Leukemia.
Iacobucci I, Mullighan CG. Iacobucci I, et al. J Clin Oncol. 2017 Mar 20;35(9):975-983. doi: 10.1200/JCO.2016.70.7836. Epub 2017 Feb 13. J Clin Oncol. 2017. PMID: 28297628 Free PMC article. Review.
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and despite cure rates exceeding 90% in children, it remains an important cause of morbidity and mortality in children and adults. The past decade has been marked by extraordinary
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and despite cure rates exceeding 90% in
Update on Lymphoblastic Leukemia/Lymphoma.
Luca DC. Luca DC. Clin Lab Med. 2021 Sep;41(3):405-416. doi: 10.1016/j.cll.2021.04.003. Clin Lab Med. 2021. PMID: 34304772 Review.
Lymphoblastic leukemias/lymphomas are predominantly diseases of childhood, where they represent almost all acute leukemias; however, they are also encountered with significant frequency in the adult population. These neoplastic processes can be of B-cell
Lymphoblastic leukemias/lymphomas are predominantly diseases of childhood, where they represent almost all acute leukem
800 results